

ASSISTANT COMMISSIONER FOR PATENTS
Washington, DC 20231



Docket No.: 200.1079CON4
Date: November 22, 2002

In re application of: Ronald M. BURCH, et al.
Serial No.: 10/056,348
Filed: January 25, 2002
For: ANALGESIC COMBINAT

ANALGESIC COMBINATION OF OXYCODONE AND NAMUMETONE

Sir:

Transmitted herewith is a **Preliminary Amendment** in the above-identified application.

- [] Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.
[] Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.
 No fee for additional claims is required.
[] A filing fee for additional claims calculated as shown below, is required:

DEC 04 2002

TECH CENTER 1600/2900

(Col. 1)		(Col. 2)		SMALL ENTITY		LARGE ENTITY		
FOR:	REMAINING	HIGHEST		RATE	FEES	OR	RATE	FEES
	AFTER	PREVIOUSLY	PRESENT					
	AMENDMENT	PAID FOR	EXTRA					
TOTAL CLAIMS	* Minus**	=		x \$ 9	\$		x \$ 18	\$
INDEP. CLAIMS	* Minus***	=		x \$ 42	\$		x \$ 84	\$
[] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+ \$140	\$		+ \$280	\$
						TOTAL:	\$	OR TOTAL

- * If the entry in Co. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 - ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 - *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

- Also transmitted herewith are:

Petition for extension under 37 C.F.R. 1.136 (in duplicate)

Other: **Information Disclosure Statement (3 pages)**

Form PTO-1449 (3 pages)

Exhibit A (15 pages)

Check(s) in the amount of **\$0.00** is/are attached to cover:

Filing fee for additional claims under 37 C.F.R. 1.16

Petition fee for extension under 37 C.F.R. 1.136

Other:

The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.

Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.

Any patent application processing fees under 37 C.F.R. 1.17.

Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.

Robert J. Paradiso, Reg. No. 41,240
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
Tel: (212) 736-1940
Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Assistant Commissioner for Patents, Washington, D.C. 20231" on November 22, 2002.

November 22, 2002.

BY: *Karen K. Karpas*

BT. , ,



200.1079.CON4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Ronald M. BURCH, et al.

RECEIVED

Serial No. 10/056,348

DEC 04 2002

Filed: January 25, 2002

TECH CENTER 1600/2900

For: ANALGESIC COMBINATION OF OXYCODONE
AND NABUMETONE

PRELIMINARY AMENDMENT

BOX Non-Fee Amendment
Assistant Commissioner for Patents
Washington, D.C. 20231

November 22, 2002

Sir:

Applicants respectfully request that the following amendments be made to the above-mentioned application:

IN THE SPECIFICATION

Please amend the **specification** as follows:

At page 13, please amend the paragraph beginning at line 25 as follows:

B1
- - Certain preferred COX-2 inhibitors include celecoxib (SC-58635), 5-bromo-s-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl] thiophene (DUP-697), flosulide (CGP-28238), meloxicam, 6-methoxy-2 naphthylacetic acid (6-MNA), Vioxx (MK-966), nabumetone (prodrug for 6-MNA), nimesulide, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398), 1-fluoro-4-[2-[4-methylsulfonyl)phenyl]-1-cyclopenten-1-yl] benzene (SC-5766), 5-(4-fluorophenyl)-1[4-(methylsulfonyl)phenyl]-3-trifluoromethyl 1H-pyrazole (SC-58215), N-[3-